Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1803 in systemic lupus erythematosus
NCT07348055Phase 2Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in systemic lupus erythematosus (SLE), sponsored by Zhixiang Jintai. Started Feb 2026; status: recruiting.
02
Drugs
velinotamig
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07348055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348055.